

Innovative Administration Systems for Vaccines

AGENDA

Thursday, December 18, 2003

8:30 A.M. – 10:00 A.M.	Introduction and Overview Chair: Jerome Donlon, M.D., Ph.D. Senior Science Advisor Department of Health and Human Services Washington, DC, USA	Plaza I/II
8:30 A.M. – 8:45 A.M.	Welcome D.A. Henderson, M.D. [invited] Principal Science Advisor Office of the Secretary Department of Health and Human Services Washington, DC, USA	
8:45 A.M. – 9:20 A.M.	Keynote Address: <i>A Needle-Free Vision</i> Myron Levine, M.D., D.T.P.H. Professor and Director, Center for Vaccine Development University of Maryland School of Medicine Baltimore, Maryland, USA	
9:20 A.M. – 9:40 A.M.	Mainstreaming New Immunization Technologies John Lloyd Associate Director, Children's Vaccine Program Program for Appropriate Technology in Health (PATH) Ferney-Voltaire, France	
9:40 A.M. – 10:00 A.M.	Grand Challenges in Global Health: Vaccine Priorities Carol Dahl, Ph.D. Associate Director Global Health Technologies Bill and Melinda Gates Foundation Seattle, Washington, USA	
10:00 A.M. – 10:15 A.M.	Break	<i>Outside Regency Room</i>
10:15 A.M. – 12:00 NOON	Transdermal Administration	Plaza I/II
10:15 A.M. – 10:20 A.M.	Chair: M. Louise Pitt, Ph.D. Chief, Department, of Aerobiology & Product Evaluation U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) Frederick, Maryland, USA	

10:20 A.M. – 10:45 A.M.	Cutaneous or Mucosal Delivery of Anthrax rPA Provides Protection against Inhalational Anthrax John A. Mikszta Team Leader, Immunology BD Technologies Research Triangle Park, North Carolina, USA	
10:45 A.M. – 11:10 A.M.	Epidermal Powder Immunization Dexiang Chen, Ph.D. Director, Vaccine Research PowderJect Vaccines Middleton, Wisconsin, USA	
11:10 A.M. – 11:35 A.M.	Completely Stable Liquid Vaccines and Disposable Safety Injectors Bruce J. Roser, Ph.D. Chief Scientist Cambridge Biostability Ltd. Cambridge, United Kingdom	
11:35 A.M. – 12:00 P.M.	Transcutaneous Immunization Gregory Glenn, M.D. Senior Vice President and Science Director IOMAI, Inc. Gaithersburg, Maryland, USA	
12:00 P.M. – 1:30 P.M.	Lunch	On Own
1:30 P.M. – 3:25 P.M.	Jet Injection of Vaccines (Part I) Chair: Bruce G. Weniger, M.D., M.P.H. Assistant Chief for Vaccine Development Immunization Safety Branch National Immunization Program Centers for Disease Control and Prevention Atlanta, Georgia, USA	Plaza I/II
1:30 P.M. – 1:55 P.M.	Overview and Challenges for Mass Vaccination with Jet Injectors (JIs) Bruce G. Weniger, M.D., M.P.H. Assistant Chief for Vaccine Development Immunization Safety Branch National Immunization Program Centers for Disease Control and Prevention Atlanta, Georgia, USA	

1:55 P.M. – 2:15 P.M.	Solving the Problems of Mass Vaccination with Needle-Free Technology Michael Mathews Vice President, Felton International, Inc. Lenexa, Kansas, USA	
2:15 P.M. – 2:40 P.M.	Safety Evaluation of Re-designed Multi-Use-Nozzle Jet Injectors (MUNJIs) for Developing Countries Martin Friede, Ph.D. Technical Officer, Initiative for Vaccine Research, Immunization Vaccines and Biologicals World Health Organization Geneva, Switzerland	
2:40 P.M. – 3:05 P.M.	Experience and Lessons from a Market-Pioneering, Disposable-Cartridge Jet Injector (DCJI): “The Future of Injection Therapy in Your Hands Today” Kurt Lynam National Sales Manager, Bioject, Inc. Portland, Oregon, USA	
3:05 P.M. – 3:25 P.M.	LectraJet ® - Needle-Free Injection System for Routine Immunization and Mass Immunization Campaigns Linda D’Antonio Vice President, D’Antonio Consultants International (DCI), Inc. East Syracuse, New York, USA	
3:25 P.M. – 4:25 P.M.	Exhibition Time and Break	Regency Room
4:25 P.M. – 5:45 P.M.	Jet Injection of Vaccines (Part II) Chair: Bruce G. Weniger, M.D., M.P.H. Assistant Chief for Vaccine Development Immunization Safety Branch National Immunization Program Centers for Disease Control and Prevention Atlanta, Georgia, USA	Plaza I/II
4:25 P.M. – 4:50 P.M.	PATH’s Experience from Jet Injector R&D and Field Assessment in Developing Countries Darin Lee Zehrung Technical Officer Program for Appropriate Technology in Health (PATH) Seattle, Washington, USA	

4:50 P.M. – 5:10 P.M.

**Roadmap Toward an International Standard
for Prefillable, Disposable Jet Injection
Cartridges for Both Routine and High-Speed
Vaccination in Developing Countries**

Martin Friede, Ph.D.

Technical Officer, Initiative for Vaccine Research
Immunization Vaccines and Biologicals
World Health Organization
Geneva, Switzerland

5:10 P.M. – 5:45 P.M.

**Panel Discussion: FDA Regulation of Combination
Products**

All Speakers on Jet Injection of Vaccines (Part I and II)

Introduction: Mark Kramer

Director, Office of Combination Products
U.S. Food and Drug Administration
Rockville, Maryland, USA

Friday, December 19, 2003

8:30 A.M. – 3:00 P.M.	Promises and Challenges for Mucosal Delivery Systems	
8:30 A.M. – 8:40 A.M.	Co-Chairs: David Klein, Ph.D. Respiratory Diseases Branch Division of Microbiology and Infectious Diseases NIAID/NIH Rockville, Maryland, USA Dennis Kopecko, Ph.D. Division of Bacterial Products Office of Vaccine Research and Review CBER/FDA Rockville, Maryland, USA	
8:40 A.M. – 9:40 A.M.	Mucosal Delivery Devices	Plaza I/II
8:40 A.M. – 9:00 A.M.	Flumist Delivery System – The First Nasal Vaccine in the U.S. James Young, Ph.D. President, MedImmune Gaithersburg, Maryland, USA	
9:00 A.M. – 9:20 A.M.	The OptiNose Bi-directional Nasal Delivery Devices for Vaccines Per G. Djupesland, M.D., Ph.D. Head of R & D and Chairman of the Board OptiNose AS Oslo, Norway	
9:20 A.M. – 9:40 A.M.	Vibrating Mesh Technology for Delivering Measles Vaccine Mark Papania, M.D., M.P.H. Team Leader, Measles, Rubella, Mumps Elimination Team Centers for Disease Control and Prevention Atlanta, Georgia	
9:40 A.M. – 11:55 A.M.	Mucosal Vectors	Plaza I/II
9:40 A.M. – 10:00 A.M.	Live Bacterial Vectors Carol Tacket, M.D. Chief, Adult Clinical Studies Section, Center for Vaccine Development University of Maryland Baltimore, Maryland, USA	

10:00 A.M. – 10:20 A.M.	Targeted Delivery of Mucosal Vaccines David Lo, M.D., Ph.D. Vice President of Integrative Biology Digital Gene Technologies La Jolla, California, USA	
10:20 A.M. – 10:35 A.M.	Break	Outside Regency Room
10:35 A.M. – 10:55 A.M.	Mucosal Immunization against Plague and Anthrax Using Microparticles James E. Eyles, Ph.D. Team Leader, Vaccine Delivery Defence Science and Technology Laboratory Porton Down Salisbury, Wiltshire, United Kingdom	
10:55 A.M. – 11:15 A.M.	Bacterial Ghosts as Carrier and Targeting Systems for Mucosal Antigen Delivery Werner Lubitz, M.D. Institute of Microbiology and Genetics, University of Vienna Vienna, Austria	
11:15 A.M. – 11:35 A.M.	VEE Replicon Vaccines in Development Jonathan Smith, Ph.D. AlphaVAX, Inc. Research Triangle Park, North Carolina, USA	
11:35 A.M. – 11:55 A.M.	Delivery of Plant-Derived Oral Vaccines Charles J. Arntzen, Ph.D. Director, Center for Infectious Diseases and Vaccinology Arizona State University Tempe, Arizona, USA	
11:55 A.M. – 1:20 P.M.	Lunch	On Own
1:20 P.M. – 2:20 P.M.	Improved Mucosal Delivery Formulations	Plaza I/II
1:20 P.M. – 1:40 P.M.	Pluronic F127-Based Systemic and Mucosal Vaccine Delivery Systems Claire Coeshott, Ph.D. RxKinetix, Inc. Louisville, Colorado, USA	

1:40 P.M. – 2:00 P.M.	The Use of Novel Biopolymers in Vaccine Encapsulation Allison Ficht, Ph.D. Director, Center for Microencapsulation and Drug Delivery Lab Texas A&M University College Station, Texas, USA	
2:00 P.M. – 2:20 P.M.	Proteosome™ Adjuvants for Nasal Vaccines against Influenza and Plague Louis F. Fries, M.D. Vice President of Clinical and Regulatory Affairs ID Biomedical Corporation Baltimore, Maryland, USA	
2:20 P.M. – 2:40 P.M.	Microparticles	Plaza I/II
2:20 P.M. – 2:40 P.M.	Formulation and Delivery Characteristics of Cochleate Vaccines Raphael Mannino, Ph.D. Executive Vice President and CEO BioDelivery Sciences International Newark, New Jersey, USA	
2:40 P.M. – 3:00 P.M.	Vectors	
2:40 P.M. – 3:00 P.M.	Phage T4 Display for Vaccine Delivery Mangala Rao, Ph.D. Walter Reed Army Institute of Research Department of Membrane Biochemistry Silver Spring, Maryland, USA	
3:00 P.M. – 3:30 P.M.	Panel Discussion	
3:30 P.M. – 4:00 P.M.	Summary and Close of Meeting	